Cell No. : Cell Name
RCB3576 : Aska-SS
update : 2024/08/14
|
| Comment | Human cell line derived from synovial sarcoma. |
| Comment from the depositor | |
| Terms and conditions | In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (Stem Cells 2010;28:1119-1131) designated by the DEPOSITOR is required. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Naka, Norifumi
|
| Originator |
Naka, Norifumi
|
| Year of deposit |
2011
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Male
|
| Age at sampling |
27 years
|
| Tissue |
subcutaneous tissue of groin
|
| Disease name |
Synovial sarcoma (Stage 4)
|
| Metastatic ability |
Yes
|
| Metastatic tissue |
Lung
|
| Classification |
cancer
|
| Year of origin |
2005
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_6C43
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
DMEM (high glucose, without Sodium pyruvate) + 20% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 2-4 split
|
| SC frequency |
|
Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Animal PCR |
|
OK
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
5
|
| User's Publication |
6
|
| Reference |
|
15489
Yokoo S, Fujiwara T, Yoshida A, Uotani K, Morita T, Kiyono M, Hasei J, Nakata E, Kunisada T, Iwata S, Yonemoto T, Ueda K, Ozaki T.
Liquid Biopsy Targeting Monocarboxylate Transporter 1 on the Surface Membrane of Tumor-Derived Extracellular Vesicles from Synovial Sarcoma
Cancers (Basel)
2021
13(8):1823
PubMed ID: 33920416
DOI: 10.3390/cancers13081823
|
|
15501
Yasui H, Imura Y, Outani H, Hamada K, Nakai T, Yamada S, Takenaka S, Sasagawa S, Araki N, Itoh K, Myoui A, Yoshikawa H, Naka N.
Trabectedin is a promising antitumour agent for synovial sarcoma
J Chemother
2016
28(5):417-24
PubMed ID: 27077926
DOI: 10.1080/1120009X.2015.1133013
|
|
16270
Toru Wakamatsu, Norifumi Naka, Satoru Sasagawa, Takaaki Tanaka, Satoshi Takenaka, Nobuhito Araki, Takafumi Ueda, Yasuko Nishizawa, Hideki Yoshikawa, Kazuyuki Itoh
Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma
Cancer Sci
2014
105(9):1124-34
PubMed ID: 24975049
DOI: 10.1111/cas.12469
|
|
15415
Yasui H, Naka N, Imura Y, Outani H, Kaneko K, Hamada K, Sasagawa S, Araki N, Ueda T, Itoh K, Myoui A, Yoshikawa H.
Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001
Cancer Lett
2014
347(1):114-22
PubMed ID: 24491407
DOI: 10.1016/j.canlet.2014.01.027
|
|
3639
Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, Joyama S, Hamada K, Tsukamoto Y, Tomita Y, Ueda T, Yoshikawa H, Itoh K.
Synovial sarcoma is a stem cell malignancy.
Stem Cells.
2010
28(7):1119-31
PubMed ID: 20518020
DOI: 10.1002/stem.452
|
| User's Publication |
|
21776
Kinoshita H, Kinoshita S, Kamoda H, Hagiwara Y, Ohtori S, Yonemoto T.
The Combination of Auranofin and Celecoxib Suppresses Local Synovial Sarcoma Progression In Vivo.
Anticancer Res
2024
44(6):2453-2458
PubMed ID: 38821602
DOI: 10.21873/anticanres.17052
|
|
19686
Takeuchi M, Nishisho T, Toki S, Kawaguchi S, Tamaki S, Oya T, Uto Y, Katagiri T, Sairyo K.
Blue light induces apoptosis and autophagy by promoting ROS-mediated mitochondr
Cancer Med
2023
12(8):9668-9683
PubMed ID: 36722116
DOI: 10.1002/cam4.5664
|
|
20225
Jayabal P, Zhou F, Lei X, Ma X, Blackman B, Weintraub ST, Houghton PJ, Shiio Y.
NELL2-cdc42 signaling regulates BAF complexes and Ewing sarcoma cell growth.
Cell Rep
2021
36(1):109254
PubMed ID: 34233189
DOI: 10.1016/j.celrep.2021.109254
|
|
20274
Su BC, Hung GY, Tu YC, Yeh WC, Lin MC, Chen JY.
Marine Antimicrobial Peptide TP4 Exerts Anticancer Effects on Human Synovial Sarcoma Cells via Calcium Overload, Reactive Oxygen Species Production and Mitochondrial Hyperpolarization.
Mar Drugs
2021
19(2)
PubMed ID: 33562681
DOI: 10.3390/md19020093
|
|
16177
Fairchild CK Jr, Floros KV, Jacob S, Coon CM, Puchalapalli M, Hu B, Harada H, Dozmorov MG, Koblinski JE, Smith SC, Domson G, Leverson JD, Souers AJ, Takebe N, Ebi H, Faber AC, Boikos SA.
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA
Cancers (Basel)
2021
13(10):2310
PubMed ID: 34065859
DOI: 10.3390/cancers13102310
|
|
14603
Michel BC, D'Avino AR, Cassel SH, Mashtalir N, McKenzie ZM, McBride MJ, Valencia AM, Zhou Q, Bocker M, Soares LMM, Pan J, Remillard DI, Lareau CA, Zullow HJ, Fortoul N, Gray NS, Bradner JE, Chan HM, Kadoch C.
A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation
Nat Cell Biol
2018
20(12):1410-1420
PubMed ID: 30397315
DOI: 10.1038/s41556-018-0221-1
|
Back
Top
CELL BANK Website
